How many 8-K filings has Adial Pharmaceuticals, Inc. filed?

Adial Pharmaceuticals, Inc. (ADIL) has 31 8-K (Current Event Report) filings on record, spanning Jan 2024 to Apr 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Adial Pharmaceuticals, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Adial Pharmaceuticals, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Adial Pharmaceuticals, Inc. (ADIL) — 8-K Filings

All 8-K filings from Adial Pharmaceuticals, Inc.. Browse 31 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (31)

ADIAL PHARMACEUTICALS Files 8-K on Equity Incentive Plan — Apr 9, 2026 Risk: low
ADIAL PHARMACEUTICALS, INC. filed an 8-K on April 9, 2026, reporting changes in officers and compensatory arrangements. Specifically, the company entered into a
ADIAL PHARMACEUTICALS, INC. Files 8-K with Material Agreement — Dec 1, 2025 Risk: medium
On November 25, 2025, ADIAL PHARMACEUTICALS, INC. entered into a material definitive agreement. The filing also disclosed unregistered sales of equity securitie
8-K Filing — Nov 14, 2025
Adial Pharmaceuticals Files 8-K Report — Sep 16, 2025 Risk: low
On September 16, 2025, ADIAL PHARMACEUTICALS, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events
Adial Pharmaceuticals Faces Delisting Concerns — Sep 3, 2025 Risk: high
Adial Pharmaceuticals, Inc. filed an 8-K on September 2, 2025, to report its notice of delisting or failure to satisfy a continued listing rule or standard. The
Adial Pharmaceuticals Files 8-K on Financials — Aug 14, 2025 Risk: low
Adial Pharmaceuticals, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition, as well as financial statements and
Adial Pharmaceuticals Files 8-K: Director, Officer, and Bylaw Updates — Aug 1, 2025 Risk: medium
On August 1, 2025, Adial Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors and changes
Adial Pharmaceuticals Files 8-K Report — Jul 16, 2025 Risk: medium
On July 14, 2025, Adial Pharmaceuticals, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but the specific details of this event are not e
Adial Pharmaceuticals Appoints New Chief Medical Officer — Jul 10, 2025 Risk: medium
On July 9, 2025, Adial Pharmaceuticals, Inc. announced the appointment of Dr. William J. R. Dean as Chief Medical Officer. Dr. Dean brings extensive experience
Adial Pharmaceuticals Enters Material Definitive Agreement — Jun 18, 2025 Risk: medium
On June 16, 2025, Adial Pharmaceuticals, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The com
Adial Pharmaceuticals Files 8-K on Shareholder Nominations — Jun 16, 2025 Risk: medium
Adial Pharmaceuticals, Inc. filed an 8-K on June 16, 2025, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11 and other events. The compa
Adial Pharmaceuticals Faces Delisting Notice — May 30, 2025 Risk: high
Adial Pharmaceuticals, Inc. filed an 8-K on May 30, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principa
Adial Pharmaceuticals Files 8-K on Financials — May 15, 2025 Risk: medium
Adial Pharmaceuticals, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
Adial Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — May 7, 2025 Risk: medium
On May 2, 2025, Adial Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities a
Adial Pharmaceuticals Files 8-K on Accountant Change — May 1, 2025 Risk: low
Adial Pharmaceuticals, Inc. filed an 8-K on May 1, 2025, reporting changes in its certifying accountant. The company, incorporated in Delaware, is located in Gl
Adial Pharma Appoints New Chief Medical Officer — Mar 21, 2025 Risk: medium
On March 20, 2025, Adial Pharmaceuticals, Inc. announced the appointment of Dr. Robert L. Smith as Chief Medical Officer. Dr. Smith brings extensive experience
Adial Pharmaceuticals Faces Delisting Concerns — Mar 7, 2025 Risk: high
Adial Pharmaceuticals, Inc. filed an 8-K on March 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filin
Adial Pharmaceuticals Files 8-K — Feb 25, 2025 Risk: low
Adial Pharmaceuticals, Inc. filed an 8-K on February 25, 2025, reporting on various events. The filing includes information related to financial statements and
Adial Pharmaceuticals Files 8-K Report — Jan 13, 2025 Risk: low
On January 13, 2025, Adial Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine upda
ADIAL PHARMACEUTICALS, INC. Files 8-K Report — Jan 8, 2025 Risk: low
On January 8, 2025, ADIAL PHARMACEUTICALS, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD
Adial Pharmaceuticals Files 8-K with Agreement Changes — Dec 18, 2024 Risk: medium
On December 13, 2024, Adial Pharmaceuticals, Inc. entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The company
Adial Pharmaceuticals Announces Board and Compensation Changes — Dec 6, 2024 Risk: medium
Adial Pharmaceuticals, Inc. announced on December 5, 2024, changes related to its board of directors and executive compensation. Specifically, the company repor
Adial Pharma Sells AD04 for $10M Upfront — Nov 18, 2024 Risk: medium
Adial Pharmaceuticals, Inc. announced on November 14, 2024, that it has entered into a definitive agreement to sell its lead drug candidate, AD04, to a third pa
Adial Pharmaceuticals Announces Board Changes and CFO Appointment — Nov 12, 2024 Risk: medium
On November 12, 2024, Adial Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, includi
Adial Pharma Appoints New Chief Medical Officer — Nov 5, 2024 Risk: medium
On November 1, 2024, Adial Pharmaceuticals, Inc. announced the appointment of Dr. Robert L. Smith as Chief Medical Officer. Dr. Smith brings extensive experienc
Adial Pharmaceuticals Appoints New Chief Medical Officer — Apr 26, 2024 Risk: medium
On April 24, 2024, Adial Pharmaceuticals, Inc. announced the appointment of Dr. Robert L. Smith as Chief Medical Officer. Dr. Smith brings extensive experience
ADIAL PHARMACEUTICALS, INC. Files 8-K — Apr 18, 2024 Risk: medium
On April 18, 2024, ADIAL PHARMACEUTICALS, INC. entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement or
Adial Pharma Appoints New CMO, Elects Director — Apr 16, 2024 Risk: medium
Adial Pharmaceuticals, Inc. announced on April 10, 2024, the appointment of Dr. Robert L. Smith as Chief Medical Officer and the election of Ms. Karen L. Smith
Adial Pharmaceuticals Files 8-K for Material Agreement — Mar 6, 2024 Risk: medium
Adial Pharmaceuticals, Inc. announced on March 1, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of
Adial Pharma Reports Executive/Director Changes, Comp Arrangements — Jan 18, 2024
Adial Pharmaceuticals, Inc. filed an 8-K on January 18, 2024, reporting an event that occurred on January 17, 2024, related to the 'Departure of Directors or Ce
Adial Pharma Files 8-K: Administrative Update, No New Financials — Jan 16, 2024
Adial Pharmaceuticals, Inc. filed an 8-K on January 16, 2024, reporting an event from January 11, 2024. This filing primarily updates administrative information

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX